NCT00550576View on ClinicalTrials.gov

Antibodies to Digoxin for Bipolar Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Bipolar Disorder
Interventions
DRUG

Digibind (Fab)

Intravenous Digibind (Digoxin Antibodies-Fab) is delivered only once in 30-45 minutes to patients after receiving the informed concent.

Trial Locations (1)

Unknown

Rambam Health Care Campus, Haifa

All Listed Sponsors
lead

Rambam Health Care Campus

OTHER

NCT00550576 - Antibodies to Digoxin for Bipolar Disorder | Biotech Hunter | Biotech Hunter